We are live on
!
Find out more
BTW
Boston Trust Walden Portfolio holdings
AUM
$12.2B
1-Year Est. Return
12.45%
This Fund
S&P 500
This Quarter
Est. Return
+7.94%
1 Year Est. Return
+12.45%
3 Year Est. Return
+44.66%
5 Year Est. Return
+68.67%
10 Year Est. Return
+295.88%
AUM
$6.82B
AUM Growth
+$400M
(+6.2%)
Cap. Flow
-$64.1M
Cap. Flow
% of AUM
-0.94%
Top 10 Holdings %
Top 10 Hldgs %
17.87%
Holding
394
New
21
Increased
124
Reduced
197
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$14.8M |
| 2 |
Henry Schein
HSIC
|
+$14.3M |
| 3 |
Honeywell
HON
|
+$14.2M |
| 4 |
Pediatrix Medical
MD
|
+$13.5M |
| 5 |
Charles River Laboratories
CRL
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$62.1M |
| 2 |
CVS Health
CVS
|
+$18M |
| 3 |
ACH
Accendra Health
ACH
|
+$14.8M |
| 4 |
Ubiquiti
UI
|
+$13.1M |
| 5 |
Eagle Bancorp
EGBN
|
+$11.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.36% |
| 2 | Healthcare | 15.63% |
| 3 | Technology | 15.4% |
| 4 | Industrials | 13.63% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Waste Management
WM
$95.9B
| $208K | ﹤0.01% |
+2,407
| New | +$196K |
|
377
Cummins
CMI
$89.2B
| $207K | ﹤0.01% |
+1,170
| New | +$200K |
|
378
Xylem
XYL
$28.7B
| $206K | ﹤0.01% |
+3,016
| New | +$200K |
|
379
Citigroup
C
$217B
| $204K | ﹤0.01% |
+2,744
| New | +$203K |
|
380
McKesson
MCK
$97.9B
| $204K | ﹤0.01% |
1,308
-168
| -11% | -$24.9K |
|
381
Sherwin-Williams
SHW
$80.5B
| $202K | ﹤0.01% |
+1,476
| New | +$194K |
|
382
Blackrock
BLK
$164B
| $201K | ﹤0.01% |
+391
| New | +$190K |
|
383
iShares Core S&P Small-Cap ETF
IJR
$110B
| $201K | ﹤0.01% |
+2,620
| New | +$198K |
|
|
BRKL
384
DELISTED
Brookline Bancorp
BRKL
| $157K | ﹤0.01% |
10,000
| – | – |
|
|
385
Eagle Bancorp
EGBN
$821M
| – | – |
-170,288
| Closed | -$11.4M |
|
386
Graco
GGG
$12.2B
| – | – |
-31,500
| Closed | -$1.3M |
|
387
Kraft Heinz
KHC
$31B
| – | – |
-2,921
| Closed | -$227K |
|
|
ACH
388
Accendra Health
ACH
$258M
| – | – |
-506,011
| Closed | -$14.8M |
|
389
Toro Company
TTC
$8.91B
| – | – |
-18,545
| Closed | -$1.15M |
|
|
390
Ubiquiti
UI
$32.3B
| – | – |
-232,980
| Closed | -$13.1M |
|
|
VIVO
391
DELISTED
Meridian Bioscience Inc
VIVO
| – | – |
-705,936
| Closed | -$10.1M |
|
|
ANDV
392
DELISTED
Andeavor
ANDV
| – | – |
-22,646
| Closed | -$2.33M |
|
|
CCC
393
DELISTED
Calgon Carbon Corp
CCC
| – | – |
-528,690
| Closed | -$11.3M |
|
|
BCR
394
DELISTED
CR Bard Inc.
BCR
| – | – |
-193,872
| Closed | -$62.1M |
|
Similar funds
GLA
PIF
II
SMDAM
JIC
MG
BS
LC
Boston Trust Walden's Q4 2017 Portfolio in Review
As of Q4 2017, Boston Trust Walden held 394 positions worth $6.82B, up 6.2% from $6.42B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Boston Trust Walden's Q4 2017 filing shows 21 new, 124 increased, 197 reduced and 10 closed positions. Its largest new stake was Charles River Laboratories: 122,536 shares worth $13.4M. The largest sale was CR Bard Inc., an estimated $62.1M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, down from 19% a quarter earlier, followed by Healthcare and Technology.
- Boston Trust Walden's largest Q4 2017 buy was Charles River Laboratories: 122,536 shares worth $13.4M.
- Boston Trust Walden added most to Becton Dickinson in Q4 2017, an estimated $14.8M increase.
- Boston Trust Walden's biggest Q4 2017 reduction was CVS Health, cutting an estimated $18M.
- Boston Trust Walden fully exited CR Bard Inc. in Q4 2017, selling an estimated $62.1M.
- Boston Trust Walden's ten largest holdings make up 18% of its $6.82B portfolio in Q4 2017.
- Boston Trust Walden opened 21 new positions and closed 10 in Q4 2017.
- Boston Trust Walden's portfolio value rose 6.2% quarter-over-quarter to $6.82B.
Based on Boston Trust Walden's 13F filing for Q4 2017, filed 29 Jan 2018.